
Strykr Analysis
BullishStrykr Pulse 68/100. EWY is cheap, ignored, and technically primed. If global rotation hits, this is first in line. Threat Level 2/5. Main risk is global risk-off or another US tech melt-up.
If you’re hunting for a market that hasn’t lost its mind, look east, far east. While the S&P 500 is busy racking up new all-time highs and US tech stocks are melting faces, South Korea’s EWY ETF sits at $205.91, dead flat, as if someone unplugged the machine. No meme stock fever, no AI-fueled FOMO, not even a whiff of the speculative euphoria that’s turned US and European indices into a casino. In a world where everything is mooning, Seoul’s market is the guy at the party quietly nursing a drink, watching everyone else lose their inhibitions.
It’s not that there’s no news. The S&P 500 closed out May at 7,580.06, a fresh record, and the headlines are a carousel of bullish takes and bubble warnings. Meanwhile, EWY has barely budged. For traders, the question isn’t just why Korea is lagging, but whether this is the last value oasis left in global equities, or a market so fundamentally out of sync that it’s best left alone.
Let’s get the facts straight. EWY, the iShares MSCI South Korea ETF, tracks a market that’s 40% Samsung and 60% “everything else,” and right now, both are snoozing. The ETF is up a whopping 0% in the last session, and volume is anemic. Compare that to the S&P’s 1.4% weekly gain, or the wild action in US tech, and you start to wonder if Korea’s market is on a different calendar. There’s no local macro shock, no central bank surprise, and the won has been stable. Earnings season passed without fireworks. The only thing moving is the global narrative, which seems to have forgotten Korea exists.
The context is even more surreal. In 2023 and 2024, Korea was the darling of the “AI supply chain” trade. Samsung, SK Hynix, and a handful of chip gear makers were supposed to be the Asian answer to Nvidia. That story fizzled. Now, with US and European markets at record valuations, Korea trades at a forward P/E barely scraping double digits. The KOSPI index is up just 2% YTD, compared to the S&P’s 13%, and foreign inflows have dried up. Global allocators are overweight US, underweight EM, and Korea is the poster child for “meh.”
But here’s the thing: the fundamentals haven’t cratered. Korea’s GDP growth is tracking 2.3% for 2026, inflation is tame, and the Bank of Korea has kept rates steady. Corporate earnings are grinding higher, and the country’s export machine is humming along, especially in semiconductors and autos. The disconnect between price and fundamentals is glaring. The market is cheap, unloved, and, crucially, liquid. For traders willing to look past the noise, that’s a setup you don’t see every cycle.
The real story is about positioning. Global funds have been dumping EMs to chase US tech, and Korea’s market has been a casualty. But with valuations stretched everywhere else, and Korea’s exporters leveraged to global capex and AI cycles, the risk-reward is starting to look asymmetric. If the US market hiccups, or if there’s a rotation out of overpriced growth into value, Korea could be the first stop for the “mean reversion” crowd. The setup is classic: low expectations, cheap multiples, and a catalyst-rich environment (AI, EVs, China reopening, take your pick).
The market’s indifference is almost comical. While everyone else is chasing the next Nvidia, Korea’s chipmakers are quietly booking record orders. The auto sector is gaining global share, and the government is pushing for shareholder-friendly reforms. Yet, the ETF sits at $205.91, as if nothing matters. For traders, that’s either a warning sign or an opportunity. The technicals are clean: EWY is coiled just below resistance at $210, with support at $200. RSI is neutral, and moving averages are converging. If volume picks up, this could be the calm before a breakout.
Strykr Watch
EWY is boxed in a tight range, with $200 as a hard floor and $210 as the ceiling. The 50-day moving average is flatlining at $205, and RSI sits at 51. Bollinger Bands are pinched, suggesting a volatility expansion is imminent. Watch for a close above $210 to trigger momentum buying, with upside to $220. On the downside, a break of $200 opens the door to $190, but that looks unlikely unless global risk-off hits. Volume is the tell, if it spikes on a green day, the rotation trade is on.
The risks are real. If US tech keeps sucking up all the oxygen, Korea could stay in the penalty box. A global risk-off event (think Fed surprise or China slowdown) would hit EWY hard. And if Samsung misses earnings or guidance, the ETF will feel it, there’s no hiding from single-stock risk here. Currency is another wildcard; a sudden move in the won could spook foreign investors. But with positioning so light, the downside looks limited compared to the upside if sentiment turns.
Opportunities abound for patient traders. A dip to $200 is a gift for value hunters, with a tight stop at $195. A breakout above $210 targets $220, and a sustained move could see EWY re-rate to the mid-$230s if global rotation picks up. For options traders, implied volatility is cheap, buying calls on a breakout or selling puts on a dip both look attractive. The asymmetric risk-reward is hard to ignore, especially with US markets looking frothy.
Strykr Take
EWY is the market’s forgotten child, but that’s exactly why it’s interesting. In a world where everything is expensive and crowded, Korea offers value, liquidity, and a clean technical setup. The next move will be violent, one way or the other. For traders bored of chasing US tech and looking for an uncorrelated play, this is your shot. Strykr Pulse 68/100. Threat Level 2/5. This is a coiled spring, not a value trap. Don’t sleep on Seoul.
Sources (5)
Why Does The S&P 500 Keep Rising On The Same Headlines?
Over the final trading week of May 2026, the S&P 500 rose 1.4% over its previous week's close to reach 7,580.06, a new record high for the index. The
An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug
We could see some of the stock market gains in our lifetime after 2026, says Fundstrat's Tom Lee
Tom Lee, Fundstrat managing partner and head of research, and Fundstrat Capital CIO, joins 'Squawk Box' to discuss the latest market trends, impact of
This Tech Stocks Rally Can Rage Into June But Markets Face 3 Big Obstacles
Memory chip inflation is just beginning, Berkshire Hathaway buys homebuilder in CEO Abel's first takeover, and other news to start your day.
Record Extremes, Alternative Investments, And The Hippo
The U.S. equity market has again pushed to the most extreme valuations in history, on the measures we find best correlated with actual subsequent mark
